NCT00052273View on ClinicalTrials.gov

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

November 30, 2004

Study Completion Date

October 31, 2005

Conditions
AdultSolid Tumor
Interventions
DRUG

capecitabine

DRUG

enzastaurin hydrochloride

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00052273 - LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter